Aycan and Enspectra partner for clinical trials on cellular imaging system

Radiology workflow and data management company Aycan Medical Systems has expanded into the clinical trials market. 

In a partnership with medical imaging diagnostics company Enspectra Health, Aycan provided imaging data management to support a pivotal clinical trial of Enspectra’s new VIO system. The first-of-its-kind technology visualizes, captures and stores images at the cellular level for more clinically accurate assessments of health. For now, VIO has received FDA clearance for use on skin after the successful proof-of-concept study.

According to a statement, the partnership between the two companies will be ongoing, with Enspectra utilizing Aycan cloud PACS and DICOM image archiving as it looks to conduct more trials to expand applications for VIO. 

Enspectra’s website states its cellular imaging capabilities will have a variety of clinical applications.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.